PIRAMAL ENTERPRISES
|
|
| BOM : 500302 NSE : PEL | |
| LT :
Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : High |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
May 20,2022 |
|
Price(EOD): ₹ 1,917.10
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 45,761.18 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| PIRAMAL ENTERPRISES | 2.3% | -13.7% | 12% |
| SUN PHARMACEUTICAL INDUSTRIES | 3.4% | -0.8% | 28% |
| DIVIS LABORATORIES | 2.1% | -3.3% | 4.4% |
| DR REDDYS LABORATORIES | 9.2% | -1.1% | -24.4% |
| CIPLA | 4.9% | -3.3% | 6.1% |
| GLAND PHARMA | -1.3% | -6.3% | 1% |
| CADILA HEALTHCARE | 3.5% | -0.9% | -44% |
| TORRENT PHARMACEUTICALS | 3.1% | -6.9% | -4.9% |
| ALKEM LABORATORIES | 3.4% | -11.9% | -1.1% |
FUNDAMENTAL ANALYSIS OF PIRAMAL ENTERPRISES
[ Q(TTM): Dec2021, Y: Mar2021
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF PIRAMAL ENTERPRISES
[As on : May 20,2022
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
32.45
P/E Calculated based on EPS of 59.07
[ Mar2021 - Consolidated Results ] 1.27
P/B Calculated based on Book Value of 1508.22
[ Mar2021 - Consolidated Results ] 3.46
P/S Calculated based on Revenues of 13231.9 Cr
[ TTM - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
-42% 117% 15% |
SHARE PRICE MOMENTUM OF PIRAMAL ENTERPRISES
PIRAMAL ENTERPRISES vs SENSEX
DEBT OF PIRAMAL ENTERPRISES
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2021 2020 2019 Avg_3yrs |
0.29 0.47 0.9 0.55 |
1.16 1.38 2.06 1.53 |
|
[Last Annual Data : Mar2021]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF PIRAMAL ENTERPRISES
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2022 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF PIRAMAL ENTERPRISES
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
22.88% 39.62% 131.11% 127.4% |
20.44% 14.76% 11.81% 8.11% |
| QtrlyTrend |
8 | |
| Latest Qtr: Dec2021 | ||
| Quarterly Result Analysis → | ||
PIRAMAL ENTERPRISES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE FINANCE | 3.3% | -6.1% | -0.9% |
| S&P BSE ALLCAP | 3.2% | -5.8% | 10.3% |
| S&P BSE 500 | 3.2% | -5.6% | 9.7% |
| S&P BSE LARGE MIDCAP | 3.1% | -5.2% | 9.2% |
| S&P BSE LARGECAP | 3.1% | -4.7% | 9.4% |
| S&P BSE 250 LARGEMIDCAP | 3.1% | -5.3% | 9.5% |
| S&P BSE 200 | 3.1% | -5.2% | 9.3% |
| S&P BSE CARBONEX | 3.1% | -4.8% | 9.4% |
| S&P BSE 100 LARGECAP TMC | 3% | -4.9% | 9.1% |
| S&P BSE 100 | 3% | -4.9% | 9.4% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY500 MULTICAP 50:25:25 | 3.4% | -6.8% | 11% |
| NIFTY FINANCE | 3.3% | -5.5% | -0.7% |
| NIFTY 500 | 3.1% | -5.7% | 9.7% |
| NIFTY 100 | 3.1% | -4.9% | 8.9% |
| NIFTY 200 | 3% | -5.3% | 9.3% |
| NIFTY LARGE MIDCAP 250 | 3% | -6% | 10.5% |
| NIFTY 100 EQUAL WEIGHT | 2.9% | -7% | 6.9% |
| NIFTY FINANCIAL SERVICES 25_50 | 2.9% | -6.1% | -1.7% |
| NIFTY NEXT 50 | 2.8% | -9.3% | 6.4% |
You may also like the below Video Courses
FAQ about PIRAMAL ENTERPRISES
Is PIRAMAL ENTERPRISES good for long term investment?
As on May 20,2022, the Fundamentals of PIRAMAL ENTERPRISES look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of PIRAMAL ENTERPRISES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is PIRAMAL ENTERPRISES UnderValued or OverValued?
As on May 20,2022, PIRAMAL ENTERPRISES is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of PIRAMAL ENTERPRISES ?
As on May 20,2022, the Intrinsic Value of PIRAMAL ENTERPRISES is Rs. 1,667.16 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 3,289.76
Fair Value [Median EV / Sales Model] : Rs. 883.19
Fair Value [Median Price / Sales Model] : Rs. 1,667.16
Median Fair Value of PIRAMAL ENTERPRISES : Rs. 1,667.16
Is PIRAMAL ENTERPRISES trading at a Premium or Discount?
As on May 20,2022, PIRAMAL ENTERPRISES is trading at a Premium of 15% based on the estimates of Median Intrinsic Value!
Check out Annual Financials of Industry Peers
Check out Quarterly Results of Industry Peers
Compare Analytics
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].
